Head-to-head evidence
lixisenatide vs TTP273
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
lixisenatide · Adlyxin / Lyxumia
Marketed by Sanofi
NCT00707031 · Phase 3 · completed
The 639 participants were randomly assigned to lixisenatide or active treatment with exenatide, but the study was not blinded. The primary HbA1c comparison met its prespecified non-inferiority criterion, with a between-group difference of 0.17 percentage points and a 95% confidence interval of 0.033 to 0.297, but HbA1c is a surrogate endpoint rather than a hard clinical outcome.
Next expected readout: June 2027 · NCT07173712 (registry estimate)
TTP273
Developed by vTv Therapeutics
NCT02653599 · Phase 2 · completed
In this randomized, double-blind, placebo-controlled trial of 174 participants, TTP273 lowered HbA1c by a statistically significant margin relative to placebo at both once-daily and twice-daily dosing, while HbA1c rose slightly in the placebo group.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: lixisenatide's landscape · TTP273's landscape